REG - RTW Biotech Opp. - Annual Financial Report

RTW Biotech OpportunitiesAnnouncement

24/04/2026 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260424:nRSX8846Ba&default-theme=true

RNS Number : 8846B  RTW Biotech Opportunities Ltd  24 April 2026

LEI: 549300Q7EXQQH6KF7Z84

24 April 2026

RTW Biotech Opportunities Ltd
(the "Company")

Annual Financial Report

A tagged copy of the Annual Report and Audited Consolidated Financial
Statements for the year ended 31 December 2025 was submitted to the National
Storage Mechanism on 24 April 2026 and is available for inspection
at https://data.fca.org.uk/artefacts/NSM/DirectUpload/NI-000143602/reports/549300Q7EXQQH6KF7Z84-2025-12-31-1-en.xhtml
(https://data.fca.org.uk/artefacts/NSM/DirectUpload/NI-000143602/reports/549300Q7EXQQH6KF7Z84-2025-12-31-1-en.xhtml)

 

 

Enquiries:

 RTW Investments, LP - Investment Manager               +44 (0)20 7959 6362

 Oliver Kenyon (Business & Corporate Development)       biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune (Investor Relations)

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com (http://www.rtwbio.com)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking statements
are subject to risks, uncertainties and assumptions, and therefore the events
in the forward-looking statements may not occur.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSEAALLADFKEFA



            Copyright 2019 Regulatory News Service, all rights reserved